The Cuban drug Jusvinza is advancing to the second phase of clinical trials, demonstrating its effectiveness in relieving pain and inflammation in secondary joints in patients recovering from the chikungunya virus.

This was reported by Julio Baldomero, director of Clinical Research at the Center for Genetic Engineering and Biotechnology (CIGB).

According to the specialist, “the final data confirmed the hypothesis put forward by the researchers.” In this regard, Baldomero stated that they managed to resolve the “painful and inflammatory symptoms of the joints caused by this virus, which is transmitted by mosquitoes and has affected tropical regions of the world.”

What is Jusvinza?

The medication is essentially an innovative therapeutic product developed at the CIGB (Center for Genetic Engineering and Biotechnology). The active ingredient “is a peptide originally designed to treat rheumatoid arthritis” that was incorporated into the Cuban national protocol during the COVID-19 pandemic for use in “severely ill patients, helping to reduce mortality on the Caribbean island before the arrival of vaccines.”

Clinical trials with promising results

In early December 2025, two clinical trials began to verify the therapeutic effect and safety of Jusvinza in these types of patients.

“The first study was conducted at the Diez de Octubre Clinical Surgical Teaching Hospital in Havana and included 174 people in the post-acute stage; while the second was carried out at the Faustino Pérez Provincial Clinical Surgical Teaching Hospital in the western province of Matanzas, with 120 individuals in the chronic stage of the disease.”

The conclusions of both studies indicate that 70 % of the patients achieved the expected results. Specialists demonstrated the efficacy and safety of the product. Furthermore, it was found that “it is not only effective in relieving joint symptoms, but its effects are long-lasting, preventing patients from developing the chronic form of the disease.”

M.Pino

Source: xinhuanet

(Reference image source: Louis Reed on Unsplash)

Follow our news on Google! For current, interesting, and accurate information, click here to see all the content on Bitfinance.news. You can also find us on X/Twitter and Instagram

La entrada Cuba tests drug that relieves painful aftereffects of Chikungunya virus apareció primero en Bitfinance.

The pharmaceutical company Moderna announced that it began the last phase of clinical trials for the development of four new vaccines against latent infections, including chickenpox and herpes, as well as the norovirus responsible for gastroenteritis outbreaks.

The four vaccines against latent infections are for diseases caused by viruses of the herpesvirus family: cytomegalovirus (the infection that causes the most birth defects in the United States), Epstein-Barr virus (the main cause of acute infectious mononucleosis), herpes virus simplex and the varicella-zoster virus (responsible for chickenpox).

In addition, the pharmaceutical company is in the last phase of development of a vaccine against norovirus, which causes outbreaks of gastroenteritis around the world and about 200,000 deaths a year.

Moderna also took the opportunity to announce a new generation vaccine against Covid-19 effective for both the omicron BA.4 and BA.5 variants and the original strains of SARS-CoV-2.

The new generation of vaccine against Covid-19 has allowed the company to develop a vaccine candidate against flu and Covid-19 for people over 50 years of age.

The company valued the global endemic Covid-19 market at $10 billion annually.

With information from Doble Llave

(Reference image source: Mufid Majnun in Unsplash)

Visit our news channel on Google News and follow us to get accurate, interesting information and stay up to date with everything. You can also see our daily content on Twitter and Instagram

La entrada Moderna prepares to launch four vaccines apareció primero en Bitfinance.

Stéphane Bancel, CEO of Moderna, reveals that the company’s experimental melanoma vaccine could reach the market in just two years, marking a historic milestone in the fight against the most serious form of skin cancer.

With 325,000 new cases and 57,000 deaths worldwide by 2020, melanoma is a global health concern.

Bancel points out that “in some countries, the product could be launched with accelerated approval by 2025″, highlighting the potential positive impact of this new therapeutic vaccine.

Unlike conventional vaccines, these therapeutic vaccines not only prevent, but also treat diseases by training the immune system against the invading agent.

Bancel describes therapeutic vaccines as “immunotherapy 2.0” and highlights the support for Moderna’s projects with the recent results of clinical trials, which reveal significant improvements in the chances of survival thanks to the vaccine.

The technology behind this breakthrough is messenger RNA (mRNA), previously successful in treating severe forms of Covid-19.

In a study of 157 people with advanced melanoma, Moderna’s vaccine, combined with Merck’s immunotherapy drug Keytruda, reduced the risk of recurrence or death by 49% over three years, compared with Keytruda alone.

Earlier results in 2022 had already shown a 44 % risk reduction over two years. Bancel highlights the growing difference in survival over time, stressing that the rate of side effects has not increased.

“We have a 50 % survival rate compared to the best product on the market. This is monumental in oncology,” says Bancel, highlighting the importance of this medical breakthrough.

K. Tovar

Source: Bancaynegocios

(Source image reference: Braňo, Unsplash)

Visit our news channel on Google News and follow us to get accurate, interesting information and stay up to date with everything. You can also see our daily content on Twitter and Instagram

La entrada Moderna hopes to offer new cancer vaccine in two years apareció primero en Bitfinance.